Skip to main content
MENU

Hypopara Newsroom

If you want to be in the know about what’s going on in the world of HypoPARA, you’ve come to the right place. Be sure to check back regularly to get the latest news updates.

Agency must show the same urgency for these Americans that it shows for treatment of COVID-19

Takeda shares the latest updates on supply interruptions of Natpara parathyroid hormone

Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs. The company is initially applying its technology to develop an oral formulation of parathyroid hormone, Oral PTH (1-34), for treatment of hypoparathyroidism and osteoporosis.

Click for more information. Let your voice be heard!

For a limited time the presentations can be viewed here on the website.

AZP-3601 is currently in development for the treatment of hypoparathyroidism

Plans move forward with phase 3 PaTHway trial

The study will be conducted at the National Institutes of Health.

By the start of next year Ascendis Pharma will be seeking participants for Phase 3

Working closely with physicians and care providers in managing hypoparathyroidism


REMEMBER
This information is provided for educational purposes only. It should not be used for diagnostic or treatment purposes. If you wish to obtain more information about this disorder, please contact your personal physician.